Preclinical vs Phase 2 — Oncology Deal Valuation Comparison

Preclinical Median Upfront

$32M

Total: $504M

Phase 2 Median Upfront

$258M

Total: $1.6B

Stage Premium

225%

Phase 2 premium over Preclinical

Preclinical Royalties

5.4%-10.7%

vs Phase 2: 11.8%-19.3%

Model Your Deal

Market Analysis

The Preclinical to Phase 2 transition in oncology represents a significant value inflection point. Phase 2 deals carry a median total deal value of $1.6B compared to $504M at Preclinical, a 225% premium reflecting clinical de-risking. Upfront payments increase from $32M to $258M.

Deal structures shift as assets advance. Preclinical deals allocate 6% to upfront and 94% to milestones, while Phase 2 deals shift to 16%/84%. Development milestones move from $236M to $345M, and royalty rates evolve from 5.4%-10.7% to 11.8%-19.3%.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the deal value premium from Preclinical to Phase 2 in oncology?

Phase 2 oncology deals command a 225% premium over Preclinical in total deal value ($1.6B vs $504M). Upfronts increase from $32M to $258M, reflecting the de-risking value of clinical progression.

How do deal structures differ between Preclinical and Phase 2 in oncology?

Preclinical deals are more milestone-weighted (94% milestones), reflecting higher clinical risk. Phase 2 deals shift toward higher upfront allocations (16% upfront) as clinical de-risking reduces the need for contingent milestone structures.

When is the optimal time to license a oncology asset?

The optimal licensing window depends on strategic priorities. Preclinical assets offer lower entry cost for licensees, while Phase 2 assets provide more certainty. The 225% premium from Preclinical to Phase 2 reflects the value created by clinical data, making the transition point critical for deal timing.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included